Do not index
By Karen Rea FNP-BC
If you spend any time around patients living with chronic knee pain, you already know how much it costs them. Not just in dollars, but in the things they quietly give up: the morning walk, the stairs they used to take without a second thought, the floor they can no longer get up from easily. Knee osteoarthritis has become one of the most common reasons people reach for pain medication day after day, and for a lot of them, the options on the table feel like a choice between living on NSAIDs and opioids or signing up for surgery.
That's exactly why I keep coming back to the regenerative medicine literature. A 2022 study published in Life (Basel) by Timmons, Sugaya, and Bane caught my attention, and I want to walk you through what they found, because it's the kind of practical, real-world data that matters for those of us doing this work every day.
The study, in plain terms
The researchers followed 30 patients dealing with knee pain. Each received an injection of cryopreserved umbilical cord tissue (UCT) directly into the affected knee joint, at a single site in the United States. Then they tracked those patients over a 24-week period to see what actually happened to their pain, their function, and their reliance on medication.
To measure all this, they used two tools that anyone in this field will recognize. The Visual Analog Scale (VAS) captures a patient's pain level both at rest and during activity. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) goes broader, scoring pain, stiffness, and physical function together. They also recorded how much pain medication each patient was taking, including opioids, NSAIDs, and acetaminophen.
What they found
The numbers tell a clear story.
Pain dropped, both at rest and on the move. Resting VAS scores improved from 1.95 to 0.83, and pain with activity fell from 6.28 all the way down to 2.87 over the 24 weeks. Both results were statistically significant (p < 0.001). That second number is the one I find most meaningful, because activity pain is what keeps people from moving, and movement is so much of what we're trying to give back to them.
Function improved measurably. Mean WOMAC scores went from 44.7 down to 18.5 (again, p < 0.001). That reflects less stiffness, less pain, and better day-to-day physical function across the group.
Medication use went way down. This is the part that stops me in my tracks every time. Of the patients who were using pain medication at the start of the study, 77.8% either reduced or eliminated it altogether. In an era where we are all rightly cautious about long-term opioid and NSAID use, that's an outcome worth paying attention to.
The researchers also looked at whether age, sex, and BMI shaped the results. They found no strong link between sex and pain scores, but they did see statistically significant correlations between both higher BMI and older age and worse pre-injection activity pain — a useful reminder that the patients walking through our doors aren't starting from the same baseline.
Why this matters for practitioners
Let me be clear about what this study is and isn't. It's a 30-patient, single-site analysis, not a large randomized controlled trial, and the authors would be the first to say more research is needed. But that doesn't make it unimportant. What it offers is a clean, well-documented look at homologous use of allogeneic umbilical cord tissue producing real, sustained improvement over six months: less pain, better function, and dramatically less reliance on medication.
For those of us in regenerative medicine, data like this does two things. It validates the conversations we're already having with patients who are searching for alternatives, and it underscores why technique and training matter so much. A promising therapy is only as good as the hands delivering it. Placement, preparation, patient selection, and proper injection technique are what separate a good outcome from a disappointing one.
That's the whole reason I do what I do. The science is moving fast, and our job is to keep up with it and to deliver it well.
Keep Learning With Us
If this kind of research excites you the way it excites me, I'd love for you to go deeper with our community.
Join us at the Regen Summit. It's where practitioners come together to learn the latest in regenerative medicine, sharpen their clinical thinking, and connect with others who are serious about doing this work at a high level. Whether you're new to the space or already deep in it, you'll leave with practical knowledge you can put to use right away.
And come train with us inside My Injection Training. Our Skool platform is built to give you hands-on, confidence-building education in injection technique, the kind of skill development that turns good science into great results for your patients. You can join the community here: skool.com/myinjectiontraining
The future of medicine is regenerative, and the best way to be ready for it is to keep learning. I hope to see you there.
— Karen Rea
This article references: Timmons RB, Sugaya K, Bane LD. "Homologous Use of Allogeneic Umbilical Cord Tissue to Reduce Knee Pain and Improve Knee Function." Life (Basel). 2022 Feb 9;12(2):260. doi: 10.3390/life12020260. This blog is for educational purposes only and does not constitute medical advice.